ABIONIC SA
Founded in 2010, Abionic is a Swiss Medtech company commercializing a revolutionary nanofluidic technology, providing healthcare professionals with a fast, simple and universal diagnostic tool. Abionic's cutting-edge Nanotechnology enhances efficiency and versatility of standard ELISA tests to deliver optimal point of care (POC) treatment options with the ability to reduce the current biological techniques from macroscale to nanoscale in a multi-analyte environment. Abionic's In Vitro Diagnostic (IVD) platform provides lab-quality results in 5 minutes from a single drop of blood at the POC enabling personalized diagnostics and the possibility of immediate treatment initiation.
Country/Area ：Switzerland
Company Email ：contact@abionic.com
Industry ：Health & MedicalHospitals & ClinicsHealthcareTools & Hardware
Company address ：5 Route De La Corniche, Epalinges, Vaud, 1066, Switzerland
Company website ：*****
Company phone ：+41 213533380
Established ：2010
Company Revenue ：$4,205,000
Number of employees ：<25
SIC Code ：80807
NAICS Code ：32325
Main Products ：ULTRA-RAPID SEPSIS BLOOD TESTabioSCOPE®SALIVA ANTIGEN TEST
Company News
Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration
Aug 9, 2022
LAUSANNE, Switzerland--(BUSINESS WIRE)-- #AMR--Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, has announced that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by BSI certification agency as complying with the European In-vitro Diagnostic Regulation (IVDR), EU 2017/746. This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union. The IVDR’s extensive requir
Aug 9, 2022
Abionic launches ultra-fast on site COVID-19 Saliva Test aimed at schools, hotels, airports and restaurantsNov 30, 2021
- Reliable and accurate test will provide unequivocal results in 1 minute, compared to rapid antigen tests (30 minutes) - Designed to be used at schools, events, companies, hotels, or airports, where swift diagnosis matter. - Reliable and easy-to-use, for the qualitative detection of...
Nov 30, 2021Abionic führt den ersten Covid-19-Schweregrad-Score ein, um die Patienten-Triage zu erleichternNov 26, 2020
BIOPÔLE, LAUSANNE, Schweiz--(BUSINESS WIRE)--Abionic SA, ein Schweizer Medtech-Unternehmen mit Sitz in Lausanne, hat den cSOFA-Score entwickelt, ein neuartiges Maß zur Bewertung des Schweregrads von Covid-19. Der cSOFA-Score (Covid Sequential Organ Failure Assessment) misst die Wahrscheinlichkeit einer klinischen Verschlechterung bei Covid-19-Patienten und ermöglicht die Triage und Zuweisung auf die allgemeine Station oder Intensivstation (ICU) bei der Aufnahme und während des Krankenhausaufent
Nov 26, 2020Abionic Launches First Covid-19 Severity Test to Triage Patients Quickly and AccuratelyNov 26, 2020
BIOPÔLE LAUSANNE, Switzerland--(BUSINESS WIRE)--Abionic launches first Covid-19 severity test to triage patients quickly and accurately
Nov 26, 2020Abionic lança a primeira testede gravidade Covid-19 para facilitar a triagem dos doentesNov 26, 2020
BIOPÔLE, LAUSANNE, Suíça--(BUSINESS WIRE)--A Abionic SA, uma empresa suíça Medtech sediada em Lausanne, desenvolveu a pontuação cSOFA, uma nova medida para avaliar a severidade da Covid-19. A pontuação cSOFA (Covid Sequential Organ Failure Assessment) mede a probabilidade de deterioração clínica nos doentes de Covid-19, permitindo a triagem e atribuição à enfermaria geral ou unidades de cuidados intensivos (UCI) aquando da admissão e durante a estadia hospitalar dos doentes. Uma pontuação baixa
Nov 26, 2020Web Summary
Q1: What is the company name and its location?
A1: The company name is Abionic SA, and it is based in Switzerland.
Q2: What industry does Abionic SA operate in?
A2: Abionic SA operates in the medical technology industry, specifically in the field of near-patient rapid diagnostics.
Q3: What is Abionic's flagship product?
A3: Abionic's flagship product is abioSCOPE, a near-patient rapid diagnostic platform that delivers lab-quality results from a drop of blood within minutes.
Q4: How does Abionic's abioSCOPE work?
A4: AbioSCOPE works by allowing a trained healthcare professional to collect 50 μL of capillary blood from a non-invasive finger-prick, transfer the sample into an abioMIX tube, and then measure biomarker levels rapidly and accurately.
Q5: What is PSP (Point-of-Sale Platform) and how does it relate to Abionic?
A5: PSP is a platform that accelerates the Time-to-Recognition of Sepsis by triggering earlier Sepsis Bundles and increasing patient survival rates. It is used in conjunction with AbioSCOPE.
Q6: What are some key facts about Abionic's products and services?
A6: Some key facts include 20+ international reference centers, 50+ global distribution channels, and over 80 peer-reviewed publications. Additionally, Abionic has FDA clearance and ISO 13485 certification.
Q7: How can Abionic's products be used in clinical settings?
A7: Abionic's products, such as abioSCOPE and PSP, can be used to diagnose sepsis early on, which is critical for patient survival. For example, a case study features an adult female patient named Athena who presented with mild abdominal pain, diarrhea, and fever, but was diagnosed with severe appendicitis after a quick PSP test.
Q8: What certifications and clearances does Abionic hold?
A8: Abionic holds IVDR/CE certificates, FDA clearance, and ISO 13485 certification.
A1: The company name is Abionic SA, and it is based in Switzerland.
Q2: What industry does Abionic SA operate in?
A2: Abionic SA operates in the medical technology industry, specifically in the field of near-patient rapid diagnostics.
Q3: What is Abionic's flagship product?
A3: Abionic's flagship product is abioSCOPE, a near-patient rapid diagnostic platform that delivers lab-quality results from a drop of blood within minutes.
Q4: How does Abionic's abioSCOPE work?
A4: AbioSCOPE works by allowing a trained healthcare professional to collect 50 μL of capillary blood from a non-invasive finger-prick, transfer the sample into an abioMIX tube, and then measure biomarker levels rapidly and accurately.
Q5: What is PSP (Point-of-Sale Platform) and how does it relate to Abionic?
A5: PSP is a platform that accelerates the Time-to-Recognition of Sepsis by triggering earlier Sepsis Bundles and increasing patient survival rates. It is used in conjunction with AbioSCOPE.
Q6: What are some key facts about Abionic's products and services?
A6: Some key facts include 20+ international reference centers, 50+ global distribution channels, and over 80 peer-reviewed publications. Additionally, Abionic has FDA clearance and ISO 13485 certification.
Q7: How can Abionic's products be used in clinical settings?
A7: Abionic's products, such as abioSCOPE and PSP, can be used to diagnose sepsis early on, which is critical for patient survival. For example, a case study features an adult female patient named Athena who presented with mild abdominal pain, diarrhea, and fever, but was diagnosed with severe appendicitis after a quick PSP test.
Q8: What certifications and clearances does Abionic hold?
A8: Abionic holds IVDR/CE certificates, FDA clearance, and ISO 13485 certification.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
